Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
Prostate Cancer and Prostatic Diseases|September 22, 2025
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patientsNeal D Shore, Christopher M Pieczonka, Sean Heron, et al.
The Journal of Urology|August 9, 2024
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate CancerNeal Shore, Christopher Pieczonka, Sean Heron, et al.
Annals of the American Thoracic Society|October 30, 2023
Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena: An Official American Thoracic Society ReportMilica Vukmirovic, Kambez H Benam, Jason J Rose, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
London Journal of Primary Care|August 8, 2018
Evaluating case studies of community-oriented integrated carePaul Thomas, Amrit Sachar, Andrew Papanikitas, et al.
JCO Oncology Practice|May 2, 2025
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate CancerSigrid V Carlsson, Pedro C Barata, Alan H Bryce, et al.
Journal of Medical Microbiology|May 16, 2022
Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settingsPeter V Coyle, Naema Hassan Al Molawi, Mohamed Ali Ben Hadj Kacem, et al.
European Urology Oncology|August 13, 2023
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM TrialNeal Shore, Mukaram Gazi, Christopher Pieczonka, et al.
The Oncologist|February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMISNeal D Shore, Christian Gratzke, Susan Feyerabend, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
Pageof 21